Zoetis Inc. $ZTS Shares Sold by Jones Financial Companies Lllp

Key Points

• Jones Financial Companies Lllp decreased its holdings in Zoetis Inc. by 45.9% in the first quarter, reducing their shares to 53,790 valued at approximately $8.86 million.
• Several hedge funds made significant changes to their positions in Zoetis, with some acquiring new holdings valued between $27,000 and $29,000 during the same quarter.
• Zoetis reported $1.76 earnings per share for the most recent quarter, exceeding expectations, with a revenue increase of 4.2% year-over-year, totaling $2.46 billion.

Jones Financial Companies Lllp reduced its position in Zoetis Inc. (NYSE:ZTS - Free Report) by 45.9% in the 1st quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 53,790 shares of the company's stock after selling 45,632 shares during the period. Jones Financial Companies Lllp's holdings in Zoetis were worth $8,857,000 as of its most recent SEC filing.

Other hedge funds have also recently bought and sold shares of the company. 1248 Management LLC purchased a new position in Zoetis in the 1st quarter valued at approximately $27,000. Saudi Central Bank purchased a new position in Zoetis in the 1st quarter valued at approximately $29,000. Cornerstone Planning Group LLC increased its stake in Zoetis by 79.3% in the 1st quarter. Cornerstone Planning Group LLC now owns 199 shares of the company's stock valued at $30,000 after purchasing an additional 88 shares in the last quarter. Migdal Insurance & Financial Holdings Ltd. increased its stake in Zoetis by 87.6% in the 1st quarter. Migdal Insurance & Financial Holdings Ltd. now owns 257 shares of the company's stock valued at $42,000 after purchasing an additional 120 shares in the last quarter. Finally, Sound Income Strategies LLC increased its stake in Zoetis by 141.4% in the 1st quarter. Sound Income Strategies LLC now owns 280 shares of the company's stock valued at $46,000 after purchasing an additional 164 shares in the last quarter. 92.80% of the stock is owned by hedge funds and other institutional investors.

Zoetis Trading Down 1.5%

ZTS traded down $2.28 during midday trading on Friday, hitting $148.33. The company's stock had a trading volume of 3,111,229 shares, compared to its average volume of 3,038,059. The company has a current ratio of 1.76, a quick ratio of 1.04 and a debt-to-equity ratio of 1.05. The firm has a market cap of $65.74 billion, a P/E ratio of 25.53, a PEG ratio of 2.40 and a beta of 0.89. The firm has a 50-day moving average price of $152.53 and a two-hundred day moving average price of $157.45. Zoetis Inc. has a 52-week low of $139.70 and a 52-week high of $200.33.

Zoetis (NYSE:ZTS - Get Free Report) last posted its quarterly earnings results on Tuesday, August 5th. The company reported $1.76 EPS for the quarter, beating the consensus estimate of $1.62 by $0.14. The company had revenue of $2.46 billion during the quarter, compared to analysts' expectations of $2.41 billion. Zoetis had a return on equity of 56.90% and a net margin of 27.83%.The firm's revenue was up 4.2% on a year-over-year basis. During the same quarter in the previous year, the business earned $1.56 EPS. Zoetis has set its FY 2025 guidance at 6.300-6.400 EPS. On average, research analysts anticipate that Zoetis Inc. will post 6.07 earnings per share for the current year.

Analyst Upgrades and Downgrades

A number of equities research analysts have commented on ZTS shares. Leerink Partners cut Zoetis from an "outperform" rating to a "market perform" rating and lowered their target price for the company from $180.00 to $155.00 in a report on Thursday, July 17th. Piper Sandler increased their target price on Zoetis from $210.00 to $215.00 and gave the company an "overweight" rating in a report on Monday, August 11th. Leerink Partnrs cut Zoetis from a "strong-buy" rating to a "hold" rating in a report on Thursday, July 17th. Argus reiterated a "buy" rating and set a $190.00 target price on shares of Zoetis in a report on Tuesday. Finally, Stifel Nicolaus cut Zoetis from a "buy" rating to a "hold" rating and lowered their target price for the company from $165.00 to $160.00 in a report on Wednesday, June 18th. Five research analysts have rated the stock with a Buy rating and four have issued a Hold rating to the stock. According to data from MarketBeat.com, Zoetis presently has an average rating of "Moderate Buy" and a consensus price target of $200.88.

About Zoetis

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.